OncoCyte Corporation — FY2016 Form 10-K
Entity and period: The supplied filing is OncoCyte Corporation’s annual report for the fiscal year ended December 31, 2016, not a filing for “Insight Molecular Diagnostics Inc.” or a standalone fourth quarter. OncoCyte was a development-stage molecular diagnostics company focused on liquid-biopsy tests for lung, breast, and bladder cancer. It had no product revenue.
Financial results and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.677 million | $4.527 million |
| General and administrative expense | $5.463 million | $4.191 million |
| Total operating expenses | $11.140 million | $8.718 million |
| Net loss | $11.168 million | $8.735 million |
| Net loss per share | $0.42 | $0.42 |
| Cash used in operating activities | $7.522 million | $4.229 million |
| Cash and cash equivalents at year-end | $10.174 million | $7.996 million |
| Total assets / total liabilities | $14.447 million / $4.585 million | $12.731 million / $2.314 million |
Operating margins are not meaningful because the company had no revenue. Cash and cash equivalents plus BioTime shares held as available-for-sale securities ($2.237 million at year-end) were $12.411 million. Year-end liabilities included $2.703 million due to BioTime, $151,000 due to affiliates, and $512,000 in capital-lease liabilities. The filing reported no funded bank loan at December 31, 2016.
Changes versus FY2015
- Net loss increased by $2.433 million; operating expenses rose 27.8%. R&D increased 25.4%, with spending increasingly directed to lung diagnostics; G&A increased 30.4%.
- Operating cash use rose by $3.293 million. Financing provided $9.881 million in net cash, principally from the August 2016 stock-and-warrant offering.
- Cash increased by $2.178 million, while total liabilities rose by $2.271 million and stockholders’ equity declined by $555,000.
Business progress, outlook, and risks
- Pipeline: The lung test was in R&D validation; breast and bladder tests were in assay development. Management targeted lung clinical validation and a potential commercial launch in the second half of 2017, contingent on successful studies and laboratory certification. These were targets, not assured outcomes.
- Preliminary evidence: A 610-sample lung proof-of-concept presentation reported AUC 0.82, sensitivity 90%, and specificity 62%. A small breast study reported AUC 0.92, sensitivity 90%, and specificity 76%. These findings do not establish commercial clinical performance. The company reported no marketed test or revenues.
- Laboratory and reimbursement: The company was establishing a CLIA laboratory and planned to seek certification in 2017. Management noted reimbursement could take years; coverage, payment rates, physician adoption, and regulatory requirements remained uncertain.
- Funding and subsequent events: Management said available resources were expected to fund current operations for at least 12 months from financial-statement issuance, but additional capital would be needed to commercialize products and continue operations. After year-end, warrant exercises generated $2.0 million on February 17, 2017. On February 21, OncoCyte entered into a Silicon Valley Bank facility providing up to $2 million, subject to draw terms; a further $3 million tranche depended on raising at least $20 million in equity, launching the lung test, and meeting other conditions. The facility is secured by substantially all assets other than specified intellectual property.
- Ownership change: Following the February 2017 warrant exercise, BioTime’s ownership fell below 50%, and BioTime deconsolidated OncoCyte effective February 17, 2017. BioTime retained significant influence and continued to provide services under a shared-facilities agreement.
- Key risks: Continued losses and financing needs; clinical or validation failure; delays in CLIA certification; possible future FDA oversight of laboratory-developed tests; uncertain reimbursement and adoption; reliance on BioTime and a limited equipment/reagent supplier; patent and license risks; and potential dilution. The company reported no material litigation and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the filing identity: the document is OncoCyte Corporation’s FY2016 10-K, despite the request metadata naming another company and quarter.
- Review subsequent filings for actual cash runway, whether the $2 million bank tranche was drawn, and any further financing or dilution.
- Check whether lung-test validation, CLIA/state laboratory certifications, launch timing, and reimbursement milestones were achieved.
- Assess whether later clinical studies reproduced the preliminary sensitivity, specificity, and AUC results in intended-use populations.
- Monitor BioTime-related service arrangements and the effect of deconsolidation, as well as the terms and status of the Wistar license.